ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
James S. Allan
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Allan, J. S.
Related Collections
Right arrow Mediastinum

Ann Thorac Surg 2003;76:218
© 2003 The Society of Thoracic Surgeons

Original article: general thoracic

Invited commentary

James S. Allan, MDa

a Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Blake 1570, Boston, MA 02114, USA

e-mail: jallan@partners.org

The first 20% of the full text of this article appears below.

The CD44 receptor is a transmembrane glycoprotein whose principal ligand is hyaluronate. As such, the CD44 receptor plays a significant role in the anchoring of cells to a basement membrane and in the maintenance of epithelial cell polarity. Altered expression of the CD44 receptor (and its splice-variant isoforms) is known to be associated with tumor progression and metastases in a variety of cancers.

Lee and colleagues have now . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.